In addition, with OPG subcutaneously injected three times a week, both tumor volume and 18F-FDG bone lesion size of Group(PAa-RANKL+OPG) were significantly smaller than Group(PAa-RANKL) and Group(PAa-RANKL+PBS) (Table 3; Figure 5). The gene discussed is TNFSF11; the disease is neoplasm.